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Abstract
Introduction Acute respiratory distress syndrome (ARDS) has
heterogeneous etiologies, rapid progressive change and a high
mortality rate. To improve the outcome of ARDS, accurate
diagnosis is essential to the application of effective early
treatment. The present study investigated the clinical effects and
safety of open lung biopsy (OLB) in patients with early-stage
ARDS of suspected non-infectious origin.
Methods We undertook a retrospective study of 41 patients
with early-stage ARDS (defined as one week or less after
intubation) who underwent OLB in two medical intensive care
units of a tertiary care hospital from 1999 to 2005. Data
analyzed included baseline characteristics, complication rate,
pathological diagnoses, treatment alterations, and hospital
survival.
Results The age of patients was 55 ± 17 years (mean ± SD).
The average ratio of arterial partial pressure of oxygen (PaO2) to
fraction of inspired oxygen (FiO2) was 116 ± 43 mmHg (mean
± SD) at biopsy. Seventeen patients (41%) were
immunocompromised. Postoperative complications occurred in
20% of patients (8/41). All biopsies provided a pathological
diagnosis with a diagnostic yield of 100%. Specific pathological
diagnoses were made for 44% of patients (18/41). Biopsy
findings led to an alteration of treatment modality in 73% of
patients (30/41). The treatment alteration rate was higher in
patients with nonspecific diagnoses than in patients with
specific diagnoses (p = 0.0024). Overall mortality was 50%
(21/41) and was not influenced by age, gender, pre-OLB
oxygenation, complication rate, pathological results, and
alteration of treatment. There was no surgery-related mortality.
The survival rate for immunocompromised patients was better
than that for immunocompetent patients (71% versus 33%; p =
0.0187) in this study.
Conclusion Our retrospective study suggests that OLB was a
useful and acceptably safe diagnostic procedure in some
selected patients with early-stage ARDS.
Introduction
The clinical definition of acute respiratory distress syndrome
(ARDS) includes the acute onset of bilateral pulmonary infil-
trates, a ratio of arterial partial pressure of oxygen (PaO2) to
fraction of inspired oxygen (FiO2) of 200 mmHg or less, and
no evidence of left atrial hypertension [1]. Many risk factors,
such as pneumonia, sepsis, and aspiration, are associated
with the development of ARDS. However, other diseases and
conditions, such as bronchiolitis obliterans organizing pneu-
monia (BOOP), adverse reaction to drugs, diffuse alveolar
hemorrhage (DAH), and hypersensitivity pneumonitis (HP),
can also cause ARDS; despite similar clinical presentations,
etiological diagnosis can be difficult especially for early-stage
ARDS. Although the mortality rate of patients with ARDS
ALI = acute lung injury; ARDS = acute respiratory distress syndrome; BAL = bronchoalveolar lavage; DAD = diffuse alveolar damage; FiO2 = fraction 
of inspired oxygen; HRCT = high-resolution computed tomography; ICU = intensive care unit; OLB = open lung biopsy; PaO2 = arterial partial pres-
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improves recently [2], the rapid clinical deterioration of such
patients, who often progress to multiple organ failure, remains
a significant challenge for intensivists in the intensive care unit
(ICU). To halt the disease progression of early-stage ARDS,
accurate diagnosis is critical.
It can be difficult to differentiate between infectious and non-
infectious etiology as the cause of ARDS in its early stages.
Current microbiological sampling techniques are insufficiently
sensitive to determine the causes of ARDS in all patients [3-
5]. In patients with negative microbiological cultures, separat-
ing a true infection from an inflammatory response with clinical
data remains problematic. Empiric broad-spectrum antibiotics
are typically prescribed to these critically ill patients immedi-
ately after admission. However, unnecessary antibiotic therapy
for non-infectious patients can enhance the occurrence of
antibiotic-resistant strains of bacteria and increase the poten-
tial for subsequent nosocomial infections.
The therapeutic benefit of prolonged glucocorticoid therapy
during the fibroproliferative stage of ARDS emphasizes the
need for the elucidation of the underlying lung pathologies [6].
Additionally, the specific diseases such as BOOP, drug reac-
tion, DAH and HP can cause an ARDS response to steroid
therapy. However, inappropriate steroid therapy for patients
with ARDS may be associated with complications such as
gastrointestinal bleeding, hyperglycemia and increased sus-
ceptibility to infection.
Some previous studies have demonstrated that open lung
biopsy (OLB) is a useful and acceptably safe diagnostic tech-
nique for patients with ARDS [7-9]. In the study by Papazian
and colleagues [7], the results of OLB directly altered the ther-
apeutic management for 34 of 36 patients with ARDS (94%),
and the OLB complication of an air leak occurred in five
patients (14%). The OLB results obtained by Patel and col-
leagues [8] led to a change in management in the majority of
57 patients with ARDS, the addition of specific therapy for 34
patients (60%), and the withdrawal of unnecessary therapy in
24 patients (37%); major complications occurred in four
patients (7%). However, in both studies the duration from intu-
bation to OLB was long: in Papazian and colleagues' study [7]
the range was 5 to 89 days, and in Patel and colleagues' study
[8] it was 0 to 25 days.
This retrospective study attempted to evaluate the utility and
safety of OLB in patients with clinically suspected non-infec-
tious early-stage ARDS.
Methods
Patients
The records of patients with ARDS who received OLB in two
ICUs at a tertiary care referral center over a five year period
between January 1999 and April 2005 were examined. Charts
with a discharge diagnosis code 518.82 of the International
Classification of Diseases, Ninth Revision, Clinical Modifica-
tion, suggesting ARDS not related to surgery or trauma, were
reviewed for possible inclusion in this study. A total of 819
patients with ARDS were identified and OLBs were performed
in 68 patients (8.3%). Forty-one OLBs were performed during
early-stage ARDS (one week or less after intubation). Patients
supported with noninvasive positive-pressure ventilation or
intubated for more than seven days at the time of biopsy were
excluded.
All patients met ARDS criteria defined by the American-Euro-
pean consensus conference [1]. Decisions to perform OLB
were made by senior intensivists in charge of the respective
ICUs. OLB was indicated when ARDS was suspected to be
noninfectious in origin, with no obvious etiology and with a
possible indication for corticosteroid treatment based on clin-
ical presentations with rapid progression, relative symmetric
distribution on chest X-ray, and predominant ground-glass
attenuation in high-resolution computed tomography (HRCT)
of the chest. Informed consent for OLB was obtained from
each patient's family.
Radiological and microbiological examinations 
performed before open lung biopsy
Chest HRCT was performed before bronchoscopic sampling
and OLB. The location for bronchoalveolar lavage (BAL) sam-
pling was selected on the basis of HRCT findings, or on a
chest X-ray when HRCT was unavailable. BAL was performed
by introducing 200 ml of sterile warm (37°C) saline solution
into a lung subsegment and aspirating it back in four 50-ml
aliquots. The first aliquot returned (bronchial fraction) was dis-
carded. Each specimen was sent for bacterial examination for
Legionella, Mycoplasma pneumoniae, Pneumocystis carinii,
and Mycobacteria, and for fungal and virological (cytomegalo-
virus, influenza virus, parainfluenza virus, adenovirus, herpes
simplex virus, respiratory syncytial virus, and coxsackie virus)
analyses. Specimens were also sent for cytology and iron stain
analysis. BAL results were deemed positive when at minimum
one microorganism grew to a concentration of more than 104
colony-forming units/ml. All procedures were performed within
24 hours of OLB.
Open lung biopsy
OLB was performed in an operating room or at the bedside in
an ICU by an experienced thoracic surgeon. Bedside OLB
was indicated when the FiO2 used reached 1 with an applied
positive end-expiratory pressure (PEEP) of at least 12 cmH2O.
With regard to mechanical ventilator settings to prevent air
leakage, PEEP was immediately reduced 2 cmH2O from the
baseline level after surgery. Pulmonary tissue was harvested
from a site considered new or from a progressive lesion iden-
tified by chest HRCT or chest X-ray.
Each tissue specimen was cultured and examined by a pulmo-
nary pathologist.Available online http://ccforum.com/content/10/4/R106
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Data collection
Medical records from these 41 patients were reviewed and
analyzed for the following data: age; gender; Acute Physiology
and Chronic Health Evaluation (APACHE) II scores at admis-
sion to the ICU; acute lung injury (ALI) scores, PEEP, and
PaO2/FiO2 ratio at ARDS diagnosis; dates of ARDS onset,
respiratory failure, intubation, and biopsy; underlying diseases;
diagnostic tests before biopsy; and medications at time of
biopsy. Results regarding complications of biopsy, pathologi-
cal diagnosis, and postoperative therapeutic changes (addi-
tion or removal of drugs) were also analyzed. Outcome
parameters, including ICU and hospital survival rates and
cause of death, were also evaluated.
Statistical analysis
For normally distributed data, values are reported as means ±
SD. Student's t tests were used to compare normally distrib-
uted continuous variables. Differences between subgroups
were compared by using the χ2 test or Fisher's exact test when
the expected number of events was less than five. The signifi-
cance level (α) for all statistical tests was set at 0.05, and p <
0.05 was considered statistically significant.
Results
Sixty-eight patients underwent OLB for ARDS evaluation dur-
ing the study period, of whom 27 were excluded because the
duration between intubation and OLB exceeded seven days.
A total of 41 patients were enrolled. Table 1 lists the baseline
characteristics of the patients studied. Twenty-four patients
(59%) were immunocompetent and 17 patients (41%) were
immunocompromised. Causes of immunocompromise status
were hematological malignancy in 10 patients and solid
tumors in four patients (three had bronchogenic cancers and
one had breast cancer), HIV infection in two patients and renal
transplantation in one. The duration from intubation to OLB for
these 41 patients was 3.0 ± 1.9 days (mean ± SD; range 1 to
7).
BAL was performed 24 hours before OLB. Findings of BAL
were compatible with pathological diagnosis for only four
patients with diagnoses of bacterial pneumonia, mycobacterial
tuberculosis, cytomegalovirus pneumonitis, and Pneumo-
cystis carinii pneumonia. Twenty-two patients (54%) had
chest HRCT before OLB to identify an appropriate biopsy site.
For the remaining 19 patients who did not undergo chest
HRCT, OLBs were performed from the right middle lobe in 12
patients and from the lingular lobe in seven patients.
Of the 41 patients, 26 (63%) underwent OLB in an operating
room and 15 (37%) received bedside OLB in an ICU. Video-
assisted thoracotomy was performed in eight patients, and the
remaining patients underwent limited anterior thoracotomy. No
intra-operative complication occurred, and eight patients
(20%) had postoperative complications (less than seven days
after the operation). Two patients developed transient hypo-
tension after OLB and regained normal status after fluid resus-
citation and vasopressor treatment for 12 hours. Two patients
had pneumothorax diagnosed by chest X-ray and required a
chest tube with low-pressure suction (10 cmH2O) drainage
for 24 hours after OLB. Two patients had subcutaneous
emphysema localized in the chest area after OLB, which
resolved spontaneously in two days. Additionally, two patients
had bronchopleural fistula with persistent air leaking from the
operative chest tube for at least one day and did not need fur-
ther surgery. Although six of these eight patients (two with
transient hypotension, one with pneumothorax, one with sub-
cutaneous emphysema and two with bronchopleural fistula)
died, no surgical complication resulted directly in death. The
incidence of postoperative complication was 15% (4/26) and
27% (4/15) for patients undergoing OLB in an operating room
or at the bedside in an ICU, respectively. Complication rates
were not significantly different between these two groups (p =
0.3799).
All biopsies provided sufficient data for pathological diagnosis
(diagnostic yield 100%). The specimens obtained during OLB
were sent for tissue culturing (for both bacteria and viruses);
all culture results were negative. Pathological diagnoses were
Table 1
Baseline characteristics
Characteristic Value
Age (years) 55 ± 17
Male sex 28 (68%)
APACHE II score 22 ± 4.9
ALI score 3.1 ± 0.4
PEEP, cmH2O 11.1 ± 3.1
PaO2/FiO2, mmHg 116 ± 43
BAL before biopsy 32 (78%)
HRCT before biopsy 22 (54%)
Underlying disease
Immunocompetent 24 (59%)
Immunocompromised 17 (41%)
Hematological malignancy 10
Solid cancer 4
HIV infection 2
Renal transplantation 1
Days from intubation to biopsy 3.0 ± 1.9
APACHE, Acute Physiology and Chronic Health Evaluation; ALI, 
acute lung injury; PEEP = positive end-expiratory pressure; PaO2, 
arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; 
BAL, bronchoalveolar lavage; HRCT, high-resolution computed 
tomography. Data are presented as mean ± SD or n (%).Critical Care    Vol 10 No 4    Kao et al.
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subdivided into specific and nonspecific categories. Eighteen
patients (44%) had specific diagnoses established by OLB,
and 23 (56%) had nonspecific diagnoses (Table 2).
Overall, OLB findings led to alteration therapy for 30 of 41
patients (73%). After OLB, 18 patients were administrated
high-dose corticosteroid therapy (1 g/day methylprednisolone
in divided doses for three days) and seven patients were
treated with low-dose corticosteroid therapy (2–3 mg/kg per
day methylprednisolone in divided doses). Three patients
received co-trimoxazole for Pneumocystis carinii pneumonia.
Antibiotics were changed in one patient and discontinued in
one patient on the basis of pathological findings. Treatment
was not changed in 11 of 41 patients (27%).
Table 3 presents comparative results for patient characteris-
tics, complication rates, alterations in treatment, and survival
rates of patients with specific and nonspecific pathological
diagnoses by OLB. The rate of treatment alteration was higher
in the nonspecific pathological diagnosis group than in that
with a specific diagnosis (56% versus 87%; p = 0.0243). No
other significant differences between these two groups were
noted.
Twenty-one patients died in the ICU, resulting in an ICU sur-
vival rate of 49% (20/41). The hospital survival rate was the
same as the ICU survival rate. Multiple organ dysfunction syn-
drome was the leading cause of death in 10 patients, followed
by septic shock in nine patients, hypovolemic shock in one
patient and acute myocardial infarction in one patient. Table 4
presents comparative results of patient characteristics and
outcomes for survivors and nonsurvivors. No significant differ-
ences were observed between survivors and nonsurvivors for
baseline data, such as age, gender, severity of illness, compli-
cation rate, and treatment alteration rate, between these two
groups. Significantly more immunocompromised patients
were in the survivor group than in the nonsurvivor group (60%
vs 24%; p = 0.0187).
Comparisons between immunocompromised and immuno-
competent patients (Table 5) showed that immunocompro-
mised patients were younger (p = 0.0004) and had lower ALI
scores (p  = 0.0045). Furthermore, immunocompromised
patients had better hospital survival rates than immunocompe-
tent patients (71% versus 33%; p = 0.0187).
Discussion
This study showed that OLB is an acceptably safe and useful
procedure for some selected patients with early-stage ARDS.
The treatment alteration rate was higher in patients with ARDS
with nonspecific pathological diagnoses than in those with
specific diagnoses.
In recent studies of patients with ARDS [7,8], OLB was
employed relatively late, and the time from intubation to OLB
was considerable (5 to 89 days in the study by Papazian and
colleagues, and 0 to 25 days in the study by Patel). In the
present study, OLB was performed within one week of intuba-
tion (3.0 ± 1.9 days), substantially earlier than in the previous
two studies.
Patel and colleagues [8] reported that the BAL results pre-
dicted OLB findings in only two of 57 patients. The indication
for OLB in the present study was suspected non-infectious
ARDS, with no obvious etiology on the basis of clinical pres-
entations. Of the 41 patients in our study, BAL results were
compatible with the pathological diagnosis in only four
patients. Most patients obtained a new diagnosis based on the
OLB results, resulting in altered treatment. These findings sug-
gest that the clinical characteristics used to indicate the appli-
cation of OLB in addition to BAL was appropriate.
Numerous pulmonary disease entities can result in ARDS;
however, the typical pulmonary pathology of ARDS is diffuse
alveolar damage (DAD) in either acute or fibroproliferative
stages. For patients with ARDS undergoing OLB, Patel and
Table 2
Pathological diagnoses
Diagnosis n
Specific 18 (44%)
Pneumocystis carinii 
pneumonia
4
Metastatic malignancy 3
Bacterial pneumonia 3
Fungal infection 2
Unusual interstitial 
pneumonitis
2
Hypersensitive pneumonitis 1
Mycobacterial tuberculosis 1
Cytomegalovirus pneumonitis 1
Metastatic calcification 1
Nonspecific 23 (56%)
Diffuse alveolar damage 12
Acute stage 2
Fibroproliferative stage 10
Fibrosis 4
Interstitial pneumonitis 3
Pulmonary edema 2
Nonspecific interstitial 
pneumonitis
1
Organizing pneumonia 1Available online http://ccforum.com/content/10/4/R106
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colleagues [8] identified the diagnostic rates of DAD and non-
DAD as 40% (23/57) and 60% (34/57), respectively. The
non-DAD diagnosis rate was higher in this study than that
obtained by Patel and colleagues (71% versus 60%). Early
OLB can obtain unexpected pathological diagnoses other
than DAD and can facilitate effective treatment for patients
with early-stage ARDS.
Table 3
Patient characteristics for specific and nonspecific diagnoses
Characteristic Specific (n = 18) Nonspecific (n = 23) p
Age 50 ± 20 58 ± 10 0.0943
Sex
Male 14 (78%) 14 (61%) 0.2482
Female 4 (21%) 9 (39%)
APACHE II score 21.8 ± 5.0 21.7 ± 4.9 0.95
ALI score 3.1± 0.3 3.2 ± 0.4 0.3
PaO2/FiO2, mmHg 120.0 ± 42.2 113.6 ± 44.8 0.6
Immune status
Compromised 10 (56%) 7 (30%) 0.1052
Competent 8 (42%) 16 (70%)
Complication rate 4 (22%) 4 (17%) 0.6985
Treatment alteration rate 10 (56%) 20 (87%) 0.0243
Hospital survival rate 6 (33%) 14 (61%) 0.08
APACHE, Acute Physiology and Chronic Health Evaluation; ALI, acute lung injury; PaO2, arterial partial pressure of oxygen; FiO2, fraction of 
inspired oxygen. Data are presented as mean ± SD or n (%); p values in italics are statistically significant.
Table 4
Patient characteristics for survivals and nonsurvivals
Characteristics Survivors (n = 20) Nonsurvivors (n = 21) p
Age 51 ± 15 59 ± 18 0.1621
Sex
Male 14 (70%) 15 (71%) 0.92
Female 6 (30%) 6 (29%)
APACHE II score 20.6 ± 3.7 23.0 ± 5.7 0.12
ALI score 3.0 ± 0.4 3.2 ± 0.3 0.1
PaO2/FiO2, mmHg 126.2 ± 44.2 107.0 ± 41.2 0.1571
Immune status
Compromised 12 (60%) 5 (24%) 0.0187
Competent 8 (40%) 16 (76%)
Complication rate 2 (10%) 6 (29%) 0.1336
Diagnosis
Specific 6 (30%) 12 (57%) 0.08
Nonspecific 14 (70%) 9 (43%)
Treatment alteration rate 16 (80%) 14 (68%) 0.3355
APACHE, Acute Physiology and Chronic Health Evaluation; ALI, acute lung injury; PaO2, arterial partial pressure of oxygen; FiO2, fraction of 
inspired oxygen. Data are presented as mean ± SD or n (%); p values in italics are statistically significant.Critical Care    Vol 10 No 4    Kao et al.
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Specific diagnosis rates based on OLB findings vary among
studies of patients with different disease entities. The specific
diagnostic rates in a review by Cheson and colleagues were
21 to 68% in immunocompetent patients and 37 to 95% in
immunocompromised patients [11-14]. In this study, specific
and nonspecific diagnostic rates were 44% (18/41) and 56%
(23/41), respectively, and specific diagnostic rates for immu-
nocompetent and immunocompromised patients were 33%
(8/24) and 59% (10/17), respectively. Although not statisti-
cally significant (p  = 0.1052), the specific diagnostic rate
between immunocompetent and immunocompromised
patients was similar to that in previous studies, indicating that
OLB obtains a high percentage of specific pathological diag-
noses for immunocompromised patients.
In this study, the rate of therapy alterations after OLB was 73%
(30/41) and was not lower than those in previous reports
(range 59 to 75%) [10,14,15]. For groups with nonspecific
and specific pathological diagnoses, the rate of changed ther-
apy was higher in the nonspecific group (87% versus 56%; p
= 0.0243). This analytical finding resulted from a large number
of patients with nonspecific pathological diagnoses undergo-
ing corticosteroid treatment as a rescue or anti-inflammatory
therapy after excluding potential active infection, such as the
fibroproliferative stage of DAD [16-18], interstitial pneumoni-
tis, nonspecific interstitial pneumonitis, and organizing pneu-
monia. Early OLB can achieve diagnoses other than fibrosis
that are potentially treatable with corticosteroid. Furthermore,
the recent study by the ARDS Clinical Trials Network [19] did
not support the routine use of methylprednisolone in patients
with persistent ARDS (at least seven days after the onset) and
suggested that methylprednisolone therapy might be harmful
when initiated more than two weeks after the onset of ARDS.
The duration of ARDS before corticosteroid treatment inter-
acted significantly with survival.
For immunocompromised patients, some studies [11,20] sug-
gested that OLB is advantageous for diagnosis and for treat-
ment alteration but that its benefit to survival remains unclear.
McKenna and colleagues [21] found that for immunocompro-
mised patients, early OLB (average 3.6 days after admission)
benefited the histological diagnosis of interstitial pneumonitis
treated with steroids; however, OLB did not improve clinical
outcome for all patients. The overall mortality rate was 51%
(21/41) in the present study, which is similar to that obtained
in previous reports (range 47 to 50%) [7,8]. More immuno-
compromised patients were in the survivors group and had a
better survival rate than the immunocompetent patients (60%
versus 24%; p = 0.0187); the young age and low ALI scores
of immunocompromised patients probably accounted in part
for their better outcome. Furthermore, the enhanced survival
rate of immunocompromised patients might be attributed to
more immunocompromised patients (9/13; 69%) than immu-
nocompetent patients (9/17; 53%) receiving high-dose corti-
costeroid therapy after active infection had been excluded by
OLB. Various pulmonary conditions such as infection, disease
progression, therapeutic reaction, new and unrelated patholo-
gies, or a combination of these can be present in immunocom-
promised patients [21,22]. For diagnostic yield and adequate
treatment, early OLB has been considered to be a reliable
diagnostic modality, providing an early and accurate etiologi-
cal diagnosis in immunocompromised patients.
Table 5
Patient characteristics for different immune status
Characteristics Competent (n = 24) Compromised (n = 17) p
Age 62 ± 15 45 ± 13 0.0004
Gender
Male 17 (71%) 12 (71%) 0.9864
Female 7 (29%) 5 (29%)
APACHE II score 22.1 ± 5.1 21.4 ± 4.9 0.6
ALI score 3.3 ± 0.4 2.9 ± 0.3 0.0045
PaO2/FiO2, mmHg 108.8 ± 44.1 130.2 ± 40.1 0.1855
Complication rate 5 (21%) 3 (18%) 0.7998
Diagnosis
Specific 9 (38%) 9 (53%) 0.3263
Nonspecific 8 (47%)
Treatment alteration rate 17 (71%) 13 (77%) 0.6882
Hospital survival rate 8 (33%) 12 (71%) 0.0187
APACHE, Acute Physiology and Chronic Health Evaluation; ALI, acute lung injury; PaO2, arterial partial pressure of oxygen; FiO2, fraction of 
inspired oxygen. Data are presented as mean ± SD or n (%); p values in italics are statistically significant.Available online http://ccforum.com/content/10/4/R106
Page 7 of 8
(page number not for citation purposes)
Operative complication rates reported for OLB in patients with
ARDS have ranged from 17 to 39% [7,8,10]. In this study, the
overall rate of OLB postoperative complications was 20% (8/
41). In the late fibrotic stage, lung parenchyma is stiffer than in
the earlier exudative or fibroproliferative stages of ARDS.
Although operative complications are multifactorial, early OLB
in non-stiff lungs (less fibrosis in the present study than in
other reports) may account for the low surgical complication
rate in this study. Of the 41 patients in the present study, 15
could not be transported to an operating room because they
were being administered 100% O2 and a high PEEP; conse-
quently, OLB was performed at the bedside in the ICU. No
intra-operative complications or exacerbation of oxygenation
and hemodynamics occurred, even in patients with ARDS with
severe hypoxemia. Of these 15 patients, four developed post-
operative complications of hypotension, pneumothorax, sub-
cutaneous emphysema, and bronchopleural fistula,
respectively. No death was attributable to OLB. The risk for
complications due to OLB in early-stage ARDS was therefore
acceptable, even for the most critically ill patients with severe
hypoxemia.
Several limitations of this study should be considered. First,
because of its retrospective nature our study cannot directly
address the question of whether early OLB has a survival ben-
efit. However, understanding of a specific etiology would per-
mit the initiation of specific therapy assuming that such a
therapy is available. Many of the diagnoses found in this study
(such as metastatic malignancy, infectious pneumonia and
hypersensitivity pneumonitis) may have an established positive
therapeutic effect on outcome. Second, the result of this study
cannot be generally applied to all patients with ARDS. The
decision to perform OLB was not made at random and the
patients referred for OLB were unlikely to be a representative
sample of our ARDS population. This selection bias of patients
and intensivists would be expected to increase the possibility
of an alternative intervention. A third limitation is that some
specific diagnosis such as viral pneumonitis may be under-
diagnosed because its identification depends on the availabil-
ity of laboratory facilities. A standardized comprehensive
microbiological examination of BAL before OLB should be
established.
Conclusion
This retrospective study demonstrates that OLB had a high
diagnostic yield rate and an acceptable complication rate for
some selected patients with early-stage ARDS. The rate of
treatment alteration was higher in patients with nonspecific
pathological diagnoses than in those with specific pathologi-
cally diagnosed ARDS. Further prospective, randomized and
control studies should investigate the appropriate indication
and effect of OLB on outcome in patients with ARDS.
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